6 faktów o mometazonie Six facts about mometasone
Article Sidebar
Published:
Dec 30, 2019
Keywords:
allergic rhinitis, intranasal corticosteroids, mometasone furoate
Main Article Content
Abstract
Intranasal corticosteroids are currently the most effective anti-inflammatory drugs in the treatment of allergic rhinitis. Advantage of intranasal corticosteroids is their strong anti-inflammatory local action and little impact on general health. According to recommendations intranasal corticosteroids are considered the first line drugs for moderate and severe intermittent and all stages of persistent allergic rhinitis. The paper presents distinguishing features of mometasone furoate.
Downloads
Download data is not yet available.
Article Details
How to Cite
Rapiejko , P. (2019). 6 faktów o mometazonie Six facts about mometasone. Alergoprofil, 15(supl. 1), 1-4. https://doi.org/10.24292/01.AP.15sup1281219
Issue
Section
Article
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Brożek JL, Bousquet J, Baena‑Cagnani CE et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126: 466-76.
2. Brożek JL, Bousquet J, Agache A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines – 2016 revision. J Allergy Clin Immunol. 2017; 140: 950-58.
3. Samoliński B, Sybilski AJ, Raciborski F et al. Prevalence of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol. Pol. 2009; 63(4): 324-30.
4. Samoliński B, Arcimowicz M (ed). Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergologia Polska. 2013: S1.
5. Rapiejko P, Jurkiewicz D. Donosowe glikokortykosteroidy w leczeniu nieżytów nosa. Terapia. 2014; 22, 10: 27-35.
6. Mygind N. Local effect of intranasal beclomethasonedipropionate aerosol in hay fever. BMJ. 1973; 4: 464-6.
7. Meltzer EO, Shekar T, Teper AA. Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2011; 32(2): 159-67.
8. Schafer T, Schnoor M, Wagenmann M et al. Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. Rhinology. 2011; 49(3): 272-80.
9. Penagos M, Compalati E, Tarantini F et al. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy. 2008; 63(10): 1280-91.
10. Small CB, Hernandez J, Reyes A et al. Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J Allergy Clin Immunol. 2005; 116(6): 1275-81.
11. Wei CC, Kennedy DW. Mometasone implant for chronic rhinosinusitis. Med Devices (Auckl). 2012; 5: 75-80.
12. Passali D, Spinosi MC, Crisanti A et al. Mometasone furoate nasal spray: a systematic review. Multidiscip Respir Med. 2016; 11: 18. https://doi.org/10.1186/s40248-016-0054-3.
13. Baena-Cagnani CE, Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr Med Res Opin. 2010; 26: 2047-55.
14. Baldwin CM, Scott LJ. Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs. 2008; 68: 1723-39.
15. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroid: clinical and therapeutic implications. Allergy. 2008; 63: 1292-1300.
16. Sörensen H, Mygind N, Pedersen CB et al. Long-term treatment of nasal polyps with beclomethasone dipropionate aerosol. III. Morphological studies and conclusions. Acta Otolaryngol (Stockh). 1976; 82: 260-2.
17. Passalacqua G, Albano M, Canonica GW et al. Inhaled and nasal corticosteroids: safety aspects. Allergy. 2000; 55: 1633.
18. Daley-Yates PT, Kunka RL, Yin Y et al. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol. 2004; 60(4): 265-8.
19. Arcimowicz M. Skuteczne i bezpieczne leczenie alergicznego nieżytu nosa. Alergoprofil. 2015; 11(3): 11-22.
20. Minshall E, Ghaffar O, Cameron L et al. Assessment by Nasal Biopsy of Long-Term Use of Mometasone Furoate Aqueous Nasal Spray (Nasonex) in the Treatment of Perennial Rhinitis. Otolaryngol Head Neck Surg. 1998; 118: 648-54.
21. Sharpe SA, Sandweiss V, Tuazon J et al. Comparison of the flow properties of aqueous suspension corticosteroid nasal sprays under differing sampling conditions. Drug Dev Ind Pharm. 2003; 29: 1005-12.
22. Rapiejko P, Sosnowski TR, Sova J et al. Deposition of intranasal glucocorticoids – preliminary study. Otolaryngol. Pol. 2015; 69(6): 30-8. https://doi.org/10.5604/00306657.1184545.
23. Sosnowski T, Rapiejko P, Sova J et al. Impact of physicochemical properties of nasal spray products on drug deposition and transport in the pediatric nasal cavity model. Int J Pharmaceutics. 2020; 574. https://doi.org/10.1016/j.ijpharm.2019.118911.
24. Salapatek AM, Patel P, Gopalan G et al. Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients. Am J Rhinol Allergy. 2010; 24: 433-8.
2. Brożek JL, Bousquet J, Agache A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines – 2016 revision. J Allergy Clin Immunol. 2017; 140: 950-58.
3. Samoliński B, Sybilski AJ, Raciborski F et al. Prevalence of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol. Pol. 2009; 63(4): 324-30.
4. Samoliński B, Arcimowicz M (ed). Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergologia Polska. 2013: S1.
5. Rapiejko P, Jurkiewicz D. Donosowe glikokortykosteroidy w leczeniu nieżytów nosa. Terapia. 2014; 22, 10: 27-35.
6. Mygind N. Local effect of intranasal beclomethasonedipropionate aerosol in hay fever. BMJ. 1973; 4: 464-6.
7. Meltzer EO, Shekar T, Teper AA. Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2011; 32(2): 159-67.
8. Schafer T, Schnoor M, Wagenmann M et al. Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. Rhinology. 2011; 49(3): 272-80.
9. Penagos M, Compalati E, Tarantini F et al. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy. 2008; 63(10): 1280-91.
10. Small CB, Hernandez J, Reyes A et al. Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J Allergy Clin Immunol. 2005; 116(6): 1275-81.
11. Wei CC, Kennedy DW. Mometasone implant for chronic rhinosinusitis. Med Devices (Auckl). 2012; 5: 75-80.
12. Passali D, Spinosi MC, Crisanti A et al. Mometasone furoate nasal spray: a systematic review. Multidiscip Respir Med. 2016; 11: 18. https://doi.org/10.1186/s40248-016-0054-3.
13. Baena-Cagnani CE, Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr Med Res Opin. 2010; 26: 2047-55.
14. Baldwin CM, Scott LJ. Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs. 2008; 68: 1723-39.
15. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroid: clinical and therapeutic implications. Allergy. 2008; 63: 1292-1300.
16. Sörensen H, Mygind N, Pedersen CB et al. Long-term treatment of nasal polyps with beclomethasone dipropionate aerosol. III. Morphological studies and conclusions. Acta Otolaryngol (Stockh). 1976; 82: 260-2.
17. Passalacqua G, Albano M, Canonica GW et al. Inhaled and nasal corticosteroids: safety aspects. Allergy. 2000; 55: 1633.
18. Daley-Yates PT, Kunka RL, Yin Y et al. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol. 2004; 60(4): 265-8.
19. Arcimowicz M. Skuteczne i bezpieczne leczenie alergicznego nieżytu nosa. Alergoprofil. 2015; 11(3): 11-22.
20. Minshall E, Ghaffar O, Cameron L et al. Assessment by Nasal Biopsy of Long-Term Use of Mometasone Furoate Aqueous Nasal Spray (Nasonex) in the Treatment of Perennial Rhinitis. Otolaryngol Head Neck Surg. 1998; 118: 648-54.
21. Sharpe SA, Sandweiss V, Tuazon J et al. Comparison of the flow properties of aqueous suspension corticosteroid nasal sprays under differing sampling conditions. Drug Dev Ind Pharm. 2003; 29: 1005-12.
22. Rapiejko P, Sosnowski TR, Sova J et al. Deposition of intranasal glucocorticoids – preliminary study. Otolaryngol. Pol. 2015; 69(6): 30-8. https://doi.org/10.5604/00306657.1184545.
23. Sosnowski T, Rapiejko P, Sova J et al. Impact of physicochemical properties of nasal spray products on drug deposition and transport in the pediatric nasal cavity model. Int J Pharmaceutics. 2020; 574. https://doi.org/10.1016/j.ijpharm.2019.118911.
24. Salapatek AM, Patel P, Gopalan G et al. Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients. Am J Rhinol Allergy. 2010; 24: 433-8.